These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10897790)

  • 1. [Use of immunosuppressors in chronic inflammatory intestinal diseases].
    Lémann M
    Gastroenterol Clin Biol; 1999 Jun; 23(5 Pt 2):B178-88. PubMed ID: 10897790
    [No Abstract]   [Full Text] [Related]  

  • 2. [Benefits and risks of immunosuppression in chronic inflammatory bowel diseases].
    Rogler G
    Dtsch Med Wochenschr; 2008 Sep; 133(38):1917-21. PubMed ID: 18785084
    [No Abstract]   [Full Text] [Related]  

  • 3. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate.
    Sandborn WJ
    Am J Gastroenterol; 1996 Mar; 91(3):423-33. PubMed ID: 8633486
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine.
    Su C; Lichtenstein GR
    Gastroenterol Clin North Am; 2004 Jun; 33(2):209-34, viii. PubMed ID: 15177535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapy of chronic inflammatory bowel diseases with azathioprine, 6-mercaptopurine and 6-thioguanine. Clinico-pharmacologic aspects].
    Schwab M; Herrlinger K; Schaeffeler E; Stange EF
    Dtsch Med Wochenschr; 2003 Feb; 128(8):378-85. PubMed ID: 12594624
    [No Abstract]   [Full Text] [Related]  

  • 6. [Immunosuppressive agents: Imurel and Purinethol].
    Groupe d'étude thérapeutique des affections inflammatoires digestives
    Rev Prat; 2005 May; 55(9):994. PubMed ID: 16052970
    [No Abstract]   [Full Text] [Related]  

  • 7. Position statement: immunomodulator therapy for inflammatory Bowel disease.
    Lavy A; Chowers Y; Odes HS; Eliakim R;
    Isr Med Assoc J; 2003 Mar; 5(3):164-9. PubMed ID: 12725133
    [No Abstract]   [Full Text] [Related]  

  • 8. Review article: monitoring of immunomodulators in inflammatory bowel disease.
    Aberra FN; Lichtenstein GR
    Aliment Pharmacol Ther; 2005 Feb; 21(4):307-19. PubMed ID: 15709982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical therapy of IBD in 2009.
    Harris A; Feller ER; Shah SA
    Med Health R I; 2009 Mar; 92(3):78-81. PubMed ID: 19385382
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunosuppressive therapy in inflammatory bowel disease.
    Hoang P; Fontaine P; Dalton HR; Gehenot M; Sibille C; Schoonbroodt D; Vanheuverzwyn R
    Acta Gastroenterol Belg; 1994; 57(5-6):333-8. PubMed ID: 7709704
    [No Abstract]   [Full Text] [Related]  

  • 11. General principles of medical therapy of inflammatory bowel disease.
    Friedman S
    Gastroenterol Clin North Am; 2004 Jun; 33(2):191-208, viii. PubMed ID: 15177534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease.
    Lees CW; Maan AK; Hansoti B; Satsangi J; Arnott ID
    Aliment Pharmacol Ther; 2008 Feb; 27(3):220-7. PubMed ID: 17988235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of conventional immunosuppressive drugs in IBD.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Zippi M
    Dig Liver Dis; 2004 Nov; 36(11):766-80. PubMed ID: 15571009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine.
    Sparrow MP; Hande SA; Friedman S; Lim WC; Reddy SI; Cao D; Hanauer SB
    Aliment Pharmacol Ther; 2005 Sep; 22(5):441-6. PubMed ID: 16128682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressors for inflammatory bowel disease: how long is long enough?
    Modigliani R
    Inflamm Bowel Dis; 2000 Aug; 6(3):251-7; discussion 158. PubMed ID: 10961598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A triangulation study of the clinician and patient experiences of the use of the immunosuppressant drugs azathioprine and 6-mercaptopurine for the management of inflammatory bowel disease.
    Holbrook K
    J Clin Nurs; 2007 Aug; 16(8):1427-34. PubMed ID: 17655530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications.
    Atreya I; Neurath MF
    Expert Rev Gastroenterol Hepatol; 2008 Feb; 2(1):23-34. PubMed ID: 19072367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel strategies in the thiopurine treatment of inflammatory bowel disease.
    Almer S
    Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):267-77. PubMed ID: 20544506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Methotrexate in the treatment of inflammatory intestinal diseases].
    Díaz Blasco J; García Valriberas R
    Rev Esp Enferm Dig; 1997 May; 89(5):385-90. PubMed ID: 9280428
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.